Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

NCT04488003 is registered in ClinicalTrials.gov with BioMed Valley Discoveries, Inc as lead sponsor.

NCT NCT04488003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04488003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Lead sponsor
BioMed Valley Discoveries, Inc
Phase
Phase 2
Overall status
Terminated
Start date
January 7, 2021
Completion date
May 23, 2023
Enrollment
104 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, braf gene alteration, braf gene mutation, map2k1 gene alteration, map2k1 gene mutation, map2k2 gene alteration, map2k2 gene mutation, mek alteration, mek mutation